Therapeutic Asset Ratings
205 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Vebreltinib
Lung Cancer
Apollomics Inc.
P2
CCC
(48)
VOLITINIB
Lung Cancer
Sun Yat-sen University
P2
CCC
(48)
Nktr-255
Lung Cancer
M.D. Anderson Cancer Center
P2
CC
(47)
egf816
Lung Cancer
SWOG Cancer Research Network
P2
CC
(46)
Cea Car-T Cells
Lung Cancer
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
Cea-Targeted Car-T
Lung Cancer
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
Lung Cancer
Bristol-Myers Squibb
P1/2
CC
(46)
Vorinostat
Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
P1/2
CC
(46)
18F-ASIS
Lung Cancer
Memorial Sloan Kettering Cancer Center
P1
CC
(44)
H-gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV4-59*01 (99.0%) -(IGHD) -IGHJ3*02 (93.3%) T125>I (114), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa
Lung Cancer
Kineta Inc.
P1/2
CC
(44)
[111in]-fpi-1967
Lung Cancer
Fusion Pharmaceuticals Inc.
P1/2
CC
(41)
[225Ac]-FPI-1966
Lung Cancer
Fusion Pharmaceuticals Inc.
P1/2
CC
(41)
3h-10000
Lung Cancer
3H Pharmaceuticals Co., Ltd.
P1/2
CC
(41)
a2b395
Lung Cancer
A2 Biotherapeutics Inc.
P1/2
CC
(41)
a2b543
Lung Cancer
A2 Biotherapeutics Inc.
P1/2
CC
(41)
a2b694
Lung Cancer
A2 Biotherapeutics Inc.
P1/2
CC
(41)
Acetazolamide
Lung Cancer
Obsidian Therapeutics, Inc.
P1/2
CC
(41)
Amivantamab-Vmjw
Lung Cancer
University of Colorado, Denver
P1/2
CC
(41)
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)-
Lung Cancer
VM Oncology, LLC
P1/2
CC
(41)
Carbon Nanoparticle-Loaded Iron
Lung Cancer
Sichuan Enray Pharmaceutical Sciences Company
P1/2
CC
(41)
Difluoromethylornithine
Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
P1/2
CC
(41)
Icasp9M28Z T Cell Infusions
Lung Cancer
Memorial Sloan Kettering Cancer Center
P1/2
CC
(41)
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Lung Cancer
University of Saskatchewan
P1/2
CC
(41)
Inupadenant
Lung Cancer
iTeos Belgium SA
P1/2
CC
(41)
Obx-115
Lung Cancer
Obsidian Therapeutics, Inc.
P1/2
CC
(41)
Showing 101 to 125 of 205 assets
Previous
Page 5 of 9
Next
